Insurance disparity in cause-specific mortalities: A SEER study on early stage, non-elderly NSCLC cancer survivors.

Authors

null

Changchuan Jiang

Icahn School of Medicine at Mount Sinai, New York, NY

Changchuan Jiang , Qian Wang , Wuyang Yang , Lei Deng , Zhengrui Xiao , Yuzhou Liu , Gabriel Albert Sara

Organizations

Icahn School of Medicine at Mount Sinai, New York, NY, Department of Internal Meidicine, Icahn School of Medicine at Mount Sinai St. Luke's and West, New York, NY, The Johns Hopkins University School of Medicine, Baltimore, MD, Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, Mount Sinai St Luke's-West Hospital, New York, NY, St Luke's-Roosevelt Hospital, New York, NY

Research Funding

Other

Background: Lung cancer is the leading cause of cancer-related death in the US. Non-elderly, early stage (stage I&II) non-small cell lung cancer (NSCLC) patients have the most promising prognosis with appropriate treatments. Studies have shown uninsured and elderly patients on Medicaid being less likely to receive guideline-concordant therapy and thus with higher mortality. However, it remains unknown how insurance status influences cause-specific survival in non-elderly NSCLC patients, and whether disparity of care is improved in this cohort after ACA. Methods: Surveillance, Epidemiology, and End Results Program from 2007-2014 was used to identify NSCLC patients on stage I and II on diagnosis. Elderly patients ( > 65 years) were excluded. Demographic and lung cancer characteristics including age, gender, race, education, income, insurance status, tumor grade/stage and treatment were analyzed. Competing risk analysis was conducted using SAS9.4. Results: A total of 13,898 patients were included. After adjusting for socio-demographic factors, tumor grade and treatment, Medicaid and non-insured were associated with higher lung cancer mortality (HR: Medicaid 1.30 (1.17-1.44), non-insured 1.26 (1.05-1.50)). Patients with any Medicaid sustain the highest mortality for cardiovascular diseases(CVD) and non-cancer respiratory diseases(NCR) across different insurance status (CVD HR: Medicaid 2.17 (1.57-2.99), non-insured 1.37 (0.74-2.56); NCR HR: Medicaid 2.46 (1.76-3.43), non-insured 0.73 (0.30-1.81)). Diagnosis after ACA was associated with lower lung cancer specific mortality but not related to CVD or NCR mortality. No effect modification was found for diagnosis after ACA on any specific cause mortality. Conclusions: Despite ACA and Medicaid expansion in 2010, Medicaid and non-insured patients have higher cancer mortality compared with insured in early-stage NSCLC patients. Furthermore, non-elderly, early-stage NSCLC cancer survivors with Medicaid have remarkably higher CVD mortality compared to private insured survivors even without any insurance, which may reflect the disparity in health literacy, primary care, and cancer survivorship care access.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Local-Regional Non–Small Cell Lung Cancer

Citation

J Clin Oncol 36, 2018 (suppl; abstr 8538)

DOI

10.1200/JCO.2018.36.15_suppl.8538

Abstract #

8538

Poster Bd #

144

Abstract Disclosures

Similar Abstracts

First Author: Qinran Liu

First Author: Qian Wang

First Author: Felipe Soares Torres